GoBroad Healthcare Group (GHG) stands at the forefront of hematologic disease treatment, combining innovative research with patient-centered care to address complex conditions like blood diseases leukemia, lymphoma, and myeloma. As a pioneer in China’s research-oriented medical model, we integrate advanced therapies, precision diagnostics, and multidisciplinary collaboration to deliver tailored solutions for patients battling blood diseases. Specializing in leukemia—a life-altering blood cancer—GoBroad’s expertise spans cutting-edge cellular immunotherapies, hematopoietic stem cell transplantation (HSCT), and groundbreaking clinical trials, offering renewed hope to those facing relapsed or refractory cases.

Precision CAR-T Therapies: Redefining Leukemia Outcomes

For patients with aggressive or recurrent leukemia, our CAR-T cell therapies have emerged as a transformative option. Targeting specific antigens like CD19, CD20, and CD22, these therapies reprogram a patient’s immune cells to seek and destroy cancerous cells. GHG has successfully treated cases of acute lymphoblastic leukemia (ALL) through sequential dual-target CAR-T approaches, achieving deep remission even in patients who relapsed after multiple transplants. One notable example includes a Russian ALL patient who, after exhausting traditional treatments, achieved complete remission following CAR-T therapy at GoBroad. The hospital’s ability to customize treatments using donor-sourced cells or novel targets like GPRC5D underscores its commitment to overcoming resistance in blood diseases. With dedicated clean rooms for cell production and a focus on minimizing complications like cytokine release syndrome, we ensure safety and efficacy at every step.

Hematopoietic Stem Cell Transplantation: Lifeline Across Ages

Hematopoietic stem cell transplantation remains a cornerstone in treating high-risk leukemia, particularly for patients unresponsive to conventional therapies. Our HSCT program caters to a wide age range—from infants as young as one month to elderly patients up to 74 years—demonstrating remarkable adaptability. We have completed thousands of transplants, utilizing techniques like TCRαβ+T cell depletion to reduce graft-versus-host disease risks. For pediatric leukemia cases, we combine HSCT with CAR-T consolidation, ensuring long-term remission while preserving quality of life. Additionally, its pioneering “Double-Insurance Dual HSCT” for thalassemia—a genetic blood disorder—boasts a 97.6% four-year survival rate, reflecting our proficiency in managing both malignant and non-malignant blood diseases.

Multidisciplinary Care: Bridging Innovation and Compassion

Treating blood diseases leukemia demands more than technical expertise; it requires holistic, coordinated care. Our multidisciplinary teams—comprising oncologists, transplant specialists, radiologists, and molecular diagnosticians—collaborate to design individualized treatment plans. For instance, patients with rare genetic conditions like Wiskott-Aldrich syndrome or severe combined immunodeficiency benefit from our allogeneic HSCT protocols, which have set global precedents. The hospital’s emphasis on rapid diagnostics, including genetic testing for mutations like BCR-ABL1, ensures timely interventions. Beyond clinical care, we supportinternational patients with language services and logistical assistance, fostering trust and accessibility.

Conclusion

GoBroad Healthcare Group redefines excellence in blood diseases leukemia management through its fusion of innovation, precision, and compassion. By advancing CAR-T therapies, expanding HSCT accessibility, and fostering multidisciplinary collaboration, we addresse leukemia and other hematologic conditions with unparalleled expertise.